Managing agitation associated with traumatic brain injury: behavioral versus pharmacologic interventions?
Flanagan
Steven R
SR
Rusk Institute of Rehabilitation Medicine, New York, NY 10016, USA.
Elovic
Elie P
EP
Sandel
Elizabeth
E
D000328:Adult; D018692:Antimanic Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D032763:Behavior Control; D001930:Brain Injuries / Q000150:complications / Q000534:rehabilitation*; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011595:Psychomotor Agitation / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D000069348:Quetiapine Fumarate; D012047:Rehabilitation Centers; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D020919:Sleep Disorders, Intrinsic / Q000188:drug therapy / Q000209:etiology; D014196:Trazodone / Q000627:therapeutic use; D014635:Valproic Acid / Q000627:therapeutic use
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate; D017367:Selective Serotonin Reuptake Inhibitors; D014196:Trazodone; D014635:Valproic Acid